50% off Premium Yearly

NASDAQ:IDXX
This summary was created by AI, based on 2 opinions in the last 12 months.
IDEXX Laboratories has recently reported impressive financial growth, experiencing a topline growth rate of around 15%, which is a significant increase compared to prior quarters that saw growth in the mid-to-high single digits. Following this announcement, the company's shares surged over 20% in a single day, signaling strong market confidence in its performance. Despite this bullish movement, there are concerns about its current valuation, as IDXX now trades at approximately 50 times its forward price-to-earnings ratio, with expected growth rates over the next few years projected at only 8%-9%. While experts express comfort in holding current positions, they advise caution regarding new investments at the present valuation levels, favoring a wait-and-see approach for potential future additions. One expert even anticipates that the stock could exceed $706, suggesting a bullish outlook in the long term.
IDEXX Laboratories is a American stock, trading under the symbol IDXX (previously IDXX-Q on Stockchase) on the NASDAQ (IDXX). It is usually referred to as NASDAQ:IDXX or IDXX
In the last year, 2 stock analysts published opinions about IDXX (previously IDXX-Q on Stockchase). 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY. Read the latest stock experts' ratings for IDEXX Laboratories.
IDEXX Laboratories was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for IDEXX Laboratories.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered IDEXX Laboratories in the last year. It is a trending stock that is worth watching.
On 2026-06-11, IDEXX Laboratories (IDXX) stock closed at a price of $557.91.
IDXX recently reported solid numbers as its topline growth accelerated to around 15% compared to previous quarters of around mid-to-high single digits. The company reacted favourably to the news as its share price jumped more than 20% in a single day. We think IDXX’s investment thesis as a high-quality, capital-light compounder in the pet healthcare industry remains intact. That being said, IDXX is now trading at around 50x Forward P/E, and growth over the next few years is expected to be around 8%-9%. We are comfortable holding the position here, but we don’t think it is too attractive to add at the current levels. We would prefer to be patient and wait for another opportunity to add to the name.
Unlock Premium - Try 5i Free